BREAST CANCER

Adam M. Brufsky, MD, PhD, ​professor of medicine, University of Pittsburgh School of Medicine, associate director of clinical investigation, University of Pittsburgh Cancer Institute, discusses the adverse effects, as well as future treatments, of anastrozole in patients with ductal carcinoma In situ (DCIS).

Howard A. “Skip” Burris, III, MD, president, Clinical Operations, chief medical officer and executive director, Drug Development Program, Sarah Cannon, discusses the novel agents in breast cancer and monoclonal antibodies.

An ongoing randomized trial in triple-negative breast cancer (TNBC) is evaluating the safety and efficacy of an antibody-drug conjugate that targets glycoprotein NMB (gpNMB), which is associated with reduced metastasis-free and overall survival.

Shannon Puhalla, MD, assistant professor of medicine, Division of Hematology/Oncology, University of Pittsburgh, discusses a phase III study examining the combination of palbociclib and fulvestrant for the treatment of patients with relapsed metastatic hormone receptor-positive, HER2-negative breast cancer.

CIB1 could represent a novel target for the development of targeted therapies in triple-negative breast cancer.

The National Comprehensive Cancer Network guidelines support genetic testing in individuals who are genetically predisposed to cancer.

The oral selective small molecule HER2 inhibitor ONT-380 in combination with other therapies demonstrated promising activity in previously treated patients with HER2-positive metastatic breast cancer, including those with CNS metastases.

Neoadjuvant ado-trastuzumab emtansine demonstrated promising complete pathological response in patients with hormone receptor-positive and HER2-positive early stage breast cancer

Massimo Cristofanilli, MD, Jefferson University Physician, professor, director, Breast Care Center, Jefferson University Hospital, discusses the next steps following the PALOMA3 trial, which was a randomized, placebo-controlled phase III study examining palbociclib plus fulvestrant in pre- and post-menopausal patients with ER-positive breast cancer.

Triple-Negative Breast Cancer

Triple-Negative Breast Cancer

Erika P. Hamilton, MD, associate director, Breast Cancer and Gynecologic Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses a phase 1b study examining ONT-380, an oral HER2-specific inhibitor, in combination with capecitabine and trastuzumab in the third-line setting and treatment of HER2-positive metastatic breast cancer.

Inhibition of the activin receptor-like kinase 1 (ALK1) protein may prevent metastasis of breast cancer, according to a study published in Cancer Research.

BRCA and other mutations occurred in more than 10% of estrogen-receptor–positive/HER2-negative invasive breast cancers in a cohort of women younger than 50 years of age, according to a report at the 2015 ASCO Annual Meeting.

Homologous repair deficiency or a high HRD score identified triple-negative breast cancers that had an increased likelihood of pathologic complete response to chemotherapy, according to a study reported at the 2015 ASCO Annual Meeting.

Adding palbociclib to standard fulvestrant more than doubled progression-free survival in pretreated patients who have HR-positive, HER2-negative breast cancer.